JP2010506942A5 - - Google Patents

Download PDF

Info

Publication number
JP2010506942A5
JP2010506942A5 JP2009533425A JP2009533425A JP2010506942A5 JP 2010506942 A5 JP2010506942 A5 JP 2010506942A5 JP 2009533425 A JP2009533425 A JP 2009533425A JP 2009533425 A JP2009533425 A JP 2009533425A JP 2010506942 A5 JP2010506942 A5 JP 2010506942A5
Authority
JP
Japan
Prior art keywords
alkyl
cyclodextrin
composition
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009533425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506942A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/080150 external-priority patent/WO2008067027A2/en
Publication of JP2010506942A publication Critical patent/JP2010506942A/ja
Publication of JP2010506942A5 publication Critical patent/JP2010506942A5/ja
Pending legal-status Critical Current

Links

JP2009533425A 2006-10-20 2007-10-02 Chk1阻害剤の組成物 Pending JP2010506942A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85305606P 2006-10-20 2006-10-20
PCT/US2007/080150 WO2008067027A2 (en) 2006-10-20 2007-10-02 Compositions of chkl inhibitors and cyclodextrin

Publications (2)

Publication Number Publication Date
JP2010506942A JP2010506942A (ja) 2010-03-04
JP2010506942A5 true JP2010506942A5 (enExample) 2010-11-18

Family

ID=39338658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533425A Pending JP2010506942A (ja) 2006-10-20 2007-10-02 Chk1阻害剤の組成物

Country Status (22)

Country Link
US (1) US8455471B2 (enExample)
EP (1) EP2063879A2 (enExample)
JP (1) JP2010506942A (enExample)
KR (2) KR20110098009A (enExample)
CN (1) CN101528215B (enExample)
AU (1) AU2007325576B2 (enExample)
BR (1) BRPI0717460A2 (enExample)
CA (1) CA2673483C (enExample)
CO (1) CO6180503A2 (enExample)
CR (1) CR10680A (enExample)
EA (1) EA200900571A1 (enExample)
IL (1) IL197869A (enExample)
MA (1) MA30872B1 (enExample)
MX (1) MX2009004214A (enExample)
MY (1) MY150649A (enExample)
NO (1) NO20091544L (enExample)
NZ (1) NZ575394A (enExample)
SV (1) SV2009003227A (enExample)
TN (1) TN2009000146A1 (enExample)
UA (1) UA95310C2 (enExample)
WO (1) WO2008067027A2 (enExample)
ZA (1) ZA200902670B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
EP2434886B1 (en) 2009-05-29 2019-10-16 CyDex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
EP2758052B9 (en) * 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
PE20142355A1 (es) 2011-10-03 2015-01-10 Respivert Ltd 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de proteinas cinasas activadas por mitogeno p38
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
PT3357919T (pt) 2014-02-14 2020-02-20 Respivert Ltd Compostos heterocíclicos aromáticos como compostos antiinflamatórios
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US9890564B2 (en) 2014-10-28 2018-02-13 Sargent Manufacturing Company Interconnected lock with direct drive for adjustable deadbolt to latchbolt spacing
JP2017155023A (ja) * 2016-03-04 2017-09-07 ジェイファーマ株式会社 Lat1阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤
EP3432880A4 (en) * 2016-03-20 2019-12-11 Asdera LLC USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNES AND NEURODEEGENERATIVE DISEASES
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
EP3618825A4 (en) * 2017-05-03 2021-01-20 Cydex Pharmaceuticals, Inc. COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
JP2020535235A (ja) 2017-09-28 2020-12-03 アスデラ エルエルシー リン脂質の調節異常が関与する疾患および障害におけるシクロデキストリンの使用
CN109078005B (zh) * 2018-08-07 2021-11-26 江苏领航生物科技有限公司 一种白消安组合物及其制备方法和应用
JP2022522928A (ja) 2018-12-18 2022-04-21 ムンディファーマ・インターナショナル・コーポレーション・リミテッド 多発性骨髄腫を治療するための化合物
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024246220A1 (en) * 2023-05-31 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating lung cancer
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
HU193933B (en) * 1984-06-08 1987-12-28 Nitrokemia Ipartelepek Herbicide or plant growth stimulating agent comprising beta-cyclodextrin complex of benzolsulphonylurea derivative and process for preparing the active substances
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
CA2320772A1 (en) * 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
MXPA02012909A (es) 2000-07-24 2004-05-05 Boehringer Ingelheim Pharma Formulaciones mejoradas de dosis oral de 1-(5-ter-butil -2-p-tiolil2h -pirazol-3 -il)-3-(4-2 (2-morfolin-4-il -etoxi) -naftalen -1-il) -urea.
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
MXPA06003110A (es) * 2003-09-17 2006-06-20 Icos Corp Uso de inhibidores de chk1 para controlar la proliferacion celular.
KR20050039573A (ko) * 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
PL1869020T3 (pl) * 2005-03-29 2011-05-31 Icos Corp Pochodne heteroarylomocznika użyteczne w hamowaniu działania CHK1
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂

Similar Documents

Publication Publication Date Title
JP2010506942A5 (enExample)
MX2010009922A (es) Activadores de piridazinona glucocinasa.
JP2015143283A5 (enExample)
JP2018511647A5 (enExample)
JP2009526034A5 (enExample)
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
ECSP055867A (es) Derivados de pirrolopirimidina
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
JP2011504903A5 (enExample)
RU2011137531A (ru) Новое производное триазина и содержащая его фармацевтическая композиция
TW200716528A (en) Cyclopropanecarboxamide derivatives
TW200628154A (en) Organic compounds
ES2374017T3 (es) Agentes terapéuticos útiles para el tratamiento del dolor.
MX2007012212A (es) 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa.
BRPI0517232A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
RU2011134283A (ru) Имидазотиазольные производные, имеющие пролиновую циклическую структуру
JP2008545718A5 (enExample)
JP2009537532A5 (enExample)
JP2011508779A5 (enExample)
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
TW200637817A (en) 5-aminoindole derivatives